Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

Wu, Lihteh, Martínez-Castellanos, María A., Quiroz-Mercado, Hugo, Arevalo, J. Fernando, Berrocal, María H., Farah, Michel E., Maia, Mauricio, Roca, José A., Rodriguez, Francisco J., for the Pan American Collaborative Retina Group (PACORES) · 2007 · Graefe's Archive for Clinical and Experimental Ophthalmology

Abstract

Background Vascular endothelial growth factor (VEGF) plays an important role in many diseases of the posterior pole that are characterized by macular edema and/or intraocular neovascularization. Recently anti-VEGF agents such as ranibizumab and pegaptanib sodium have been shown to be beneficial in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (ARMD). However in most parts of the world, both pegaptanib sodium and ranibizumab are not readily available. Bevacizumab, a humanized recombinant monoclonal IgG antibody that binds and inhibits all VEGF isoforms, has been proposed as an alternative treatment option.Methods A total of 1,265 consecutive patients were injected with bevacizumab for diseases such as proliferative diabetic retinopathy, diabetic macular edema, retinal vein occlusions, and CNV of several etiologies including ARMD at eight Latin American institutions from 1 September 2005 to 31 January 2006. Of these 1,265, 92 were excluded because they were injected once and lost to follow-up. The remaining 1,173 patients constitute the subjects of this retrospective, multicenter, open label, uncontrolled interventional case series that reports the cumulative systemic and ocular adverse events following intravitreal bevacizumab during 12 months of follow-up. Patients were examined at baseline and then monthly. If the patients were unable to attend the 12-month visit, a telephone interview was conducted to assess for possible systemic complications.Results A total of 4,303 intravitreal injections of bevacizumab on 1,310 eyes was reported. All 1,173 patients were accounted for at the 12-month visit. Systemic adverse events were reported in 18 (1.5%) patients. These included seven (0.59%) cases of an acute elevation of systemic blood pressure, six (0.5%) cerebrovascular accidents, five (0.4%) myocardial infarctions, two (0.17%) iliac artery aneurysms, two (0.17%) toe amputations and five (0.4%) deaths. Ocular complications included seven (0.16%) bacterial endophthalmitis, seven (0.16%) tractional retinal detachments, four (0.09%) uveitis, and a case (0.02%) each of rhegmatogenous retinal detachment and vitreous hemorrhage.Conclusion Despite the limited follow-up, repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00417-007-0660-z

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

See all 465

Metadata

Authors
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES)
Affiliations
  • University of Puerto Rico System (PR)
  • Universidade Federal de São Paulo (BR)
Corresponding author
Wu, Lihteh
Venue
Graefe's Archive for Clinical and Experimental Ophthalmology
Published
2007-08-03
Volume
246
Issue
1
Pages
81-87
ISSN
  • 0721-832X (ISSN-L)
  • 1435-702X
OpenAlex
W2029119558
Cited by
456
References
34
Citations by year
2026: 5 · 2025: 8 · 2024: 8 · 2023: 5 · 2022: 12 · 2021: 12 · 2020: 14 · 2019: 15 · 2018: 13 · 2017: 23 · 2016: 18 · 2015: 25 · 2014: 35 · 2013: 40 · 2012: 37
FWCI
43.89
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Graefe s Archive for Clinical and Experimental Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
  • UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
Keywords
bevacizumab, intravitreal injection, drug safety, adverse events, choroidal neovascularization, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, anti-VEGF therapy, bacterial endophthalmitis, vitreous hemorrhage, retinal detachment, systemic hypertension, stroke
MeSH terms
Bevacizumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Diabetic Retinopathy, Female, Humans, Injections, Macular Degeneration, Macular Edema, Male, Middle Aged, Retinal Vein Occlusion, Retrospective Studies, Time Factors, Visual Acuity, Vitreous Body, Treatment Outcome, Retreatment, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). https://app.cochat.ai/papers/10.1007/s00417-007-0660-z
The paper
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES). (2007). Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-007-0660-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.